During the past decade, Hospital das Clínicas da Faculdade de Medicina de Botucatu conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 4 clinical trials were completed, i.e. on average, 28.6% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 4 clinical trials were completed. i.e. 36.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital das Clínicas da Faculdade de Medicina de Botucatu" #1 sponsor was "UPECLIN HC FM Botucatu Unesp" with 3 trials, followed by "Bayer" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Hospital de Clinicas de Porto Alegre" with 2 trials sponsored and "United Therapeutics" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital das Clínicas da Faculdade de Medicina de Botucatu" #1 collaborator was "Chugai Pharmaceutical" with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator, "ADIR, a Servier Group company" with 1 trials as a collaborator, "Brainomix Limited" with 1 trials as a collaborator and "Chiesi Farmaceutici S.p.A." with 1 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Hospital das Clínicas da Faculdade de Medicina de Botucatu" are "Covid19" (3 trials), "Atypical Hemolytic Uremic Syndrome" (2 trials), "Pulmonary Arterial Hypertension" (2 trials), "Retinopathy of Prematurity (ROP)" (2 trials) and "COVID-19" (1 trials). Many other conditions were trialed in "Hospital das Clínicas da Faculdade de Medicina de Botucatu" in a lesser frequency.

Most popular intervention types in "Hospital das Clínicas da Faculdade de Medicina de Botucatu" are "Drug" (13 trials), "Procedure" (3 trials), "Device" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Crovalimab" (2 trials), "Eylea (Aflibercept, BAY86-5321)" (2 trials), "Laser photocoagulation" (2 trials) and "Thrombectomy" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hospital das Clínicas da Faculdade de Medicina de Botucatu" are 17 trials for "All" genders.

Currently, there are NaN active trials in "Hospital das Clínicas da Faculdade de Medicina de Botucatu". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Hospital das Clínicas da Faculdade de Medicina de Botucatu, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital das Clínicas da Faculdade de Medicina de Botucatu, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".